(Q37097159)

18 August 2017

Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis (English)

1 reference

18 August 2017

0 references

1 reference

0 references

1

Amit Bar-Or

1 reference

18 August 2017

Mark S Freedman

2

1 reference

18 August 2017

Marcelo Kremenchutzky

3

1 reference

18 August 2017

Françoise Menguy-Vacheron

4

1 reference

18 August 2017

Deborah Bauer

5

1 reference

18 August 2017

Stefan Jodl

6

1 reference

18 August 2017

Philippe Truffinet

7

1 reference

18 August 2017

Myriam Benamor

8

1 reference

18 August 2017

Scott Chambers

9

1 reference

18 August 2017

Paul W O'Connor

10

1 reference

18 August 2017

language of work or name

English

0 references

publication date

12 July 2013

1 reference

18 August 2017

7

1 reference

based on heuristic

inferred from page(s)

published in

Neurology

1 reference

18 August 2017

81

1 reference

18 August 2017

6

1 reference

18 August 2017

552-558

1 reference

Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years

18 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744268

Pathophysiology of multiple sclerosis and the place of teriflunomide

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744268

Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744268

Effects of influenza vaccination and influenza illness on exacerbations in multiple sclerosis.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744268

Magnetic resonance imaging outcomes from a phase III trial of teriflunomide

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744268

Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744268

A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744268

Immune response to influenza vaccine is maintained in patients with multiple sclerosis receiving interferon beta-1a

3 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23851964

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1212/WNL.0B013E31829E6FBF

1 reference

18 August 2017

1 reference

18 August 2017

1 reference